insulin, FDA and Biosimilar
FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes
Merilog is the third insulin biosimilar product approved by the FDA and joins the two long-acting insulin biosimilar products approved in 2021 by the FDA. Approval of biosimilar products can increase patient access to safe and effective treatment options.
Use of the long-acting insulin analogs glargine and detemir does not reduce the risk of diabetic ketoacidosis in children and adolescents with type 1 diabetes mellitus (T1DM), compared with the ...
Trials including commercially available formulations of insulin detemir or insulin glargine were compared with NPH. Pertinent English-language clinical trials published between 2000 and 2006 were ...
“Rescinding the cap on insulin at $35 only makes pharmaceutical richer and everyday Americans, including MAGA voters, seriously poorer,” Steven Bechloss—author of the Substack, America, America — ...
The FDA approved its short-acting insulin, Fiasp (insulin aspart injection) in September, and its long-acting insulin Tresiba (insulin degludec) got US approval late last year.
ZME Science on MSN4mon
Scientists Create ‘Smart’ Insulin That Activates Only When Needed — A “Holy Grail” For DiabetesOne wrong move — a little too much insulin or a forgotten dose ... This could improve both the short-term and long-term ...
Diabetes is a number of diseases that involve problems with the hormone insulin. There is no cure for diabetes. The warning signs of diabetes can be so mild that you don't notice them. That's ...
Key market drivers of the Insulin Pen and Pump market include the rising prevalence of diabetes, advancements in insulin delivery technologies ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback